Prevention of ovarian hyperstimulation syndrome in a rat model: Efficacy comparison between cabergoline and meloxicam

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 5, 2010, Pages 692-699

  Saylan, Arif ^a   Arioz, Dagistan Tolga ^a   Koken, Tulay ^a   Dilek, Husniye ^a   Saylan, Filiz ^a   Yilmazer, Mehmet ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

Animal model; Cabergoline; Meloxicam; OHSS; VEGF

Indexed keywords

CABERGOLINE; MELOXICAM; UNCLASSIFIED DRUG; VASCULOTROPIN; ZELOXIM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LOW DRUG DOSE; NONHUMAN; OVARY HYPERSTIMULATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; BODY WEIGHT; CHORIONIC GONADOTROPIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERGOLINES; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; ORGAN SIZE; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION INDUCTION; PREGNANCY; PREGNANCY, ANIMAL; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, WISTAR; THIAZINES; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951846239     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016341003592537     Document Type: Article

References (24)

1. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril. 1978;30:255-68.
2. Gomez R, Simon C, Remohi J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod. 2003;68:2164-71.
3. Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology. 2002;143:4339-48.
4. Amarin ZO. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. An aggressive, but perhaps life-saving procedure. Hum Reprod. 2003;18:659-64.
5. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147:5400-11.
6. Quintana R, Kopcow L, Marconi G, Young E, Yovanovich C, Paz DA. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril. 2008;90:1511-16.
7. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulose and theca/lutein cells. Role in corpus luteum development. Am J Pathol. 1995;146:157-65.
8. Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulose cells in vitro. J Clin Endocrinol Metab. 1993;77:1723-5.
9. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/VP factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 1995;80:1967-71.
10. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with upregulation of vascular endothelial growth factor. J Clin Endocrinol Metab. 2002;87:3300-8.
11. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma Clin Cancer Res. 2003;9:1648-55.
12. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther. 2003;3:263-76.
13. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001;7:569-74.
14. Mornex R, Orgiazzi J, Hugues B, Gagnaire JC, Claustrat B. Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors. J Clin Endocrinol Metab. 1978;47:290-5.
15. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996;10:333-7.
16. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63:268-72.
17. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB. Vascular endothelial growth factor localization in human ovary and follopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab. 1996;81:353-9.
18. Otani N, Minami S, Yamoto M, Shikone T, Otani H, Nishiyama R, et al. The vascular endothelial growth factor/fms-like tyrosine kinaz system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab. 1999;84:3845-51.
19. Bata MS, Al-Ramahi M, Salhab AS, Gharaibeh MN, Schwartz J. Delay of ovulation by meloxicam in healthy cycling volunteers: a placebo-controlled, double-blind, crossover study. J Clin Pharmacol. 2006;46:925-32.
20. Athanasiou S, Bourne TH, Khalid A, Okokon EV, Crayford TJ, Hagström HG, et al. Effects of indomethacin on follicular structure, vascularity, and function ovary the periovulatory period in women. Fertil Steril. 1996;65:556-60.
21. Landgren BM, Unen AL, Dicfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. Acta Endocrinol. 1980;94:89-98.
22. Smith G. Roberts R, Hall C, Nuki G. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with anti-inflammatory arthritis taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol. 1996;35:458-62.
23. Akil M, Amos RS, Stewart P. Infertility may sometimes be associated with NSAID consumption. Br J Rheumatol. 1996;35:76-8.
24. Mendonca L, Khamashta M, Nelson-Piercy EI, Hunt BJ, Hughes GR. Nonsteroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology. 2000;39:880-2.